Refractory Langerhans cell histiocytosis Recruiting Phase 2 Trials for Tipifarnib (DB04960)

DBCOND0022006 (Refractory Langerhans cell histiocytosis)Recruiting2 IdentifierTitlePurposeDrugs
NCT03155620Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Screening
NCT04284774Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialTreatment